Agios director granted options and RSUs

AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom received new equity awards as part of his compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom received new equity awards as part of his compensation. He was granted stock options for 14,950 shares of common stock at an exercise price of $34.16 per share, vesting in full on June 18, 2027 and expiring on June 18, 2036.

He also received 2,927 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in full on June 18, 2027, with shares to be delivered within three business days after vesting. These are routine awards, not open-market purchases or sales.

Insider Trade Summary

Grant/Award: 17,877 shares

Grant/Award 2 txns

Insider Backstrom Jay T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted stock units	2,927	$0.00	$0.00
Grant/Award	Stock options (right to buy)	14,950	$0.00	$0.00

Holdings After Transaction: Restricted stock units — 2,927 contracts (Direct); Stock options (right to buy) — 14,950 contracts (Direct)

Footnotes (3)

F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Key Figures

Stock options granted: 14,950 options Option exercise price: $34.16 per share Option expiration: June 18, 2036 +2 more

5 metrics

Stock options granted 14,950 options Grant on June 18, 2026; 100% vest on June 18, 2027

Option exercise price $34.16 per share Exercise price for 14,950 stock options

Option expiration June 18, 2036 Expiration date of granted stock options

RSUs granted 2,927 RSUs Grant on June 18, 2026; vest in full June 18, 2027

Shares per RSU 1 share per RSU Each restricted stock unit equals one common share

Key Terms

Restricted stock units, Stock options, contingent right, exercise price, +1 more

5 terms

Restricted stock units financial

"The restricted stock units were granted on June 18, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock options financial

"These options were granted on June 18, 2026."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

exercise price financial

"conversion_or_exercise_price": "34.1600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The shares underlying these options vest as to 100% of the underlying shares"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Agios (AGIO) director Jay Backstrom report in this Form 4?

Jay T. Backstrom reported receiving equity compensation awards from Agios. He was granted stock options and restricted stock units tied to Agios common stock, reflecting routine director compensation rather than open-market buying or selling of existing shares.

How many stock options did Jay Backstrom receive from Agios (AGIO)?

Jay Backstrom received stock options for 14,950 shares of Agios common stock. These options have an exercise price of $34.16 per share and vest 100% on June 18, 2027, providing potential future ownership if exercised after vesting.

What are the terms of Jay Backstrom’s restricted stock units at Agios (AGIO)?

He received 2,927 restricted stock units, each equal to one share of Agios common stock. The units were granted June 18, 2026 and vest in full on June 18, 2027, with vested shares delivered within three business days after vesting.

Are Jay Backstrom’s Agios (AGIO) Form 4 transactions open-market buys or sells?

No, the Form 4 shows grant or award acquisitions, not market trades. Both the stock options and restricted stock units were awarded at a zero purchase price, reflecting equity compensation rather than open-market buying or selling activity.

When do Jay Backstrom’s Agios (AGIO) stock options expire?

The stock options granted to Jay Backstrom on June 18, 2026 expire on June 18, 2036. They vest fully on June 18, 2027, giving him several years after vesting to decide whether to exercise them at the $34.16 strike price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 05:12 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Backstrom Jay T.

(Last)

(First)

(Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted stock units	⁽¹⁾	06/18/2026		A		2,927		⁽²⁾	⁽²⁾	Common stock	2,927	$0	2,927	D
Stock options (right to buy)	$34.16	06/18/2026		A		14,950		⁽³⁾	06/18/2036	Common stock	14,950	$0	14,950	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

3. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Remarks:

	/s/ William Cook, as attorney-in-fact for Jay Backstrom	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR